Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Viva Biotech Holdings (1873.HK)
Shanghai, CN
Viva Biotech Holdings, founded in 2008 and based in Shanghai, China, operates as an investment holding company primarily dedicated to providing comprehensive, structure-based drug discovery services to biotechnology and pharmaceutical clients worldwide. Its extensive discovery biology offerings encompass protein expression and purification, structural biology, hit identification, bioassay development, biomolecular interaction analysis, and pharmacokinetic studies. The company also delivers a suite of chemistry services, including medicinal and synthetic chemistry, analytical services, preparative purification, and computer-aided drug design, all supported by robust chemical technology platforms. Viva Biotech further specializes in antibody drug research and development, covering antigen preparation, multi-species antibody discovery, monoclonal antibody production, functional screening and characterization, antibody engineering, and cell line engineering. This work is facilitated by cutting-edge technological platforms such as hybridoma, phage and yeast display, mammalian display, VHH antibody technology, high-throughput sequencing, computer-aided drug design, HDX-MS, protein crystal structure determination, and SPR technology. Beyond its core service offerings, Viva Biotech provides various biological resources, including cell lines, crystal structures, GPCR proteins, antibodies, and other purified proteins. The company also offers contract development and manufacturing (CDMO) services for small molecule active pharmaceutical ingredients (APIs) and their intermediates. Furthermore, it engages in the trading of APIs, intermediates, and formulations, and operates under an "equity for service" model. Additional services include general research, laboratory facility rentals, project management and bidding assistance, and the sale of chemical compounds.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.80% | -8.70% | -25.00% | -42.73% | -35.71% | -30.00% | -29.21% | -15.44% | -88.42% | -71.49% | -71.49% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%-13.0% Q4'25: -11.4% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%+50.0% ★ Q4'25: +181.5% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%+3.8% ★ Q4'25: +5.0% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%+11.2% ★ Q4'25: +8.6% (vs Q4'23)
-
ROIC Biotechnology: -16.1%+3.9% ★ Q4'25: +6.1% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%-18.4% ★ Q4'25: +1.4% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×3.45× Q4'25: 1.95× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. |
Dec 2029 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
323.06M
est: 357.73M (-9.7%)
|
696.96M
est: 893.97M (-22.0%)
|
2.10B
est: 2.79B (-24.6%)
|
2.38B
est: 3.10B (-23.1%)
|
2.16B
est: 2.86B (-24.6%)
|
1.99B
est: 2.97B (-33.0%)
|
1.73B
est: 1.83B (-5.3%)
|
2.21B
2.21B – 2.21B
+20.9% YoY
|
2.55B
2.55B – 2.55B
+15.3% YoY
|
2.87B
2.87B – 2.87B
+12.8% YoY
|
862.76M
862.76M – 862.76M
-70.0% YoY
|
| EBITDA |
88.37M
est: 70.96M (+24.5%)
|
164.35M
est: 366.42M (-55.1%)
|
369.94M
est: 952.79M (-61.2%)
|
436.35M
est: 1.39B (-68.5%)
|
391.01M
est: 2.71B (-85.6%)
|
428.00M
est: 580.91M (-26.3%)
|
385.38M
est: 357.53M (+7.8%)
|
432.23M
432.23M – 432.23M
+20.9% YoY
|
498.44M
498.44M – 498.44M
+15.3% YoY
|
562.38M
562.38M – 562.38M
+12.8% YoY
|
168.90M
168.90M – 168.90M
-70.0% YoY
|
| EBIT |
54.32M
est: 42.27M (+28.5%)
|
112.54M
est: 377.73M (-70.2%)
|
236.90M
est: 982.18M (-75.9%)
|
265.98M
est: 1.43B (-81.4%)
|
192.68M
est: 2.79B (-93.1%)
|
229.67M
est: 321.12M (-28.5%)
|
193.25M
est: 197.64M (-2.2%)
|
238.93M
238.93M – 238.93M
+20.9% YoY
|
275.53M
275.53M – 275.53M
+15.3% YoY
|
310.88M
310.88M – 310.88M
+12.8% YoY
|
93.37M
93.37M – 93.37M
-70.0% YoY
|
| Net Income |
265.87M
est: 254.35M (+4.5%)
|
-386.88M
est: 352.26M (-209.8%)
|
287.55M
est: 915.96M (-68.6%)
|
-528.48M
est: -436.26M (-21.1%)
|
-116.11M
est: 256.14M (-145.3%)
|
167.29M
est: 361.69M (-53.7%)
|
219.76M
est: 233.84M (-6.0%)
|
291.16M
291.16M – 291.16M
+24.5% YoY
|
388.19M
388.19M – 388.19M
+33.3% YoY
|
—
— – —
-100.0% YoY
|
—
— – —
|
| SGA |
54.79M
est: 62.46M (-12.3%)
|
123.26M
est: 74.99M (+64.4%)
|
321.70M
est: 194.99M (+65.0%)
|
404.45M
est: 283.57M (+42.6%)
|
409.66M
est: 554.54M (-26.1%)
|
364.12M
est: 537.32M (-32.2%)
|
361.86M
est: 330.70M (+9.4%)
|
399.80M
399.80M – 399.80M
+20.9% YoY
|
461.05M
461.05M – 461.05M
+15.3% YoY
|
520.19M
520.19M – 520.19M
+12.8% YoY
|
156.23M
156.23M – 156.23M
-70.0% YoY
|
| EPS |
0.19
est: 0.09 (+114.3%)
|
-0.25
est: -0.10 (-155.7%)
|
0.15
est: 0.22 (-31.9%)
|
-0.28
est: 0.18 (-256.5%)
|
-0.06
est: 0.13 (-144.8%)
|
0.08
est: 0.20 (-61.0%)
|
0.10
est: 0.10 (-1.2%)
|
0.12
0.12 – 0.12
+24.5% YoY
|
0.17
0.17 – 0.17
+33.3% YoY
|
—
— – —
-100.0% YoY
|
—
— – —
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-28 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-27 | B | 3/5 | 2/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-26 | B | 3/5 | 2/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-22 | B | 3/5 | 2/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-21 | B | 3/5 | 2/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-20 | B | 3/5 | 2/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-19 | B | 3/5 | 2/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-18 | B+ | 3/5 | 2/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-15 | B+ | 3/5 | 2/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-14 | B+ | 3/5 | 2/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-13 | B+ | 3/5 | 2/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-12 | B+ | 3/5 | 2/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-11 | B+ | 3/5 | 2/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-08 | A- | 4/5 | 2/5 | 3/5 | 4/5 | 2/5 | 4/5 | 5/5 |
| 2026-05-07 | A- | 4/5 | 2/5 | 3/5 | 4/5 | 2/5 | 4/5 | 5/5 |
| 2026-05-06 | A- | 4/5 | 2/5 | 3/5 | 4/5 | 2/5 | 4/5 | 5/5 |
| 2026-05-05 | A- | 4/5 | 2/5 | 3/5 | 4/5 | 2/5 | 4/5 | 5/5 |
| 2026-05-04 | A- | 4/5 | 2/5 | 3/5 | 4/5 | 2/5 | 4/5 | 5/5 |
| 2026-04-30 | A- | 4/5 | 2/5 | 3/5 | 4/5 | 2/5 | 4/5 | 5/5 |
| 2026-04-29 | B+ | 3/5 | 2/5 | 3/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-28 | B+ | 3/5 | 2/5 | 3/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-27 | B+ | 3/5 | 2/5 | 3/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-24 | B+ | 3/5 | 2/5 | 3/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-23 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-22 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-21 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-20 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-17 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-16 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 5/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.02% | 25.8K | 0.42% |
| 2 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.01% | 104.3K | 0.65% |
| 3 | Avantis Responsible Emerging Markets Equity ETF AVSE | 0.00% | 8.4K | 0.33% |
| 4 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 323.7K | 0.39% |
| 5 | Avantis Emerging Markets Equity UCITS ETF USD Acc AVEM.L | 0.00% | 8.3K | 0.35% |
| 6 | State Street SPDR Portfolio Emerging Markets ETF SPEM | 0.00% | 510.0K | 0.07% |
| 7 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 122.4K | 0.29% |
| 8 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 152.0K | 0.28% |
| 9 | Avantis Emerging Markets Equity ETF AVEM | 0.00% | 282.0K | 0.33% |
| 10 | Avantis Emerging Markets Value ETF AVES | 0.00% | 1.4K | 0.36% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chen Cheney Mao | Chairman & Chief Executive Officer | 5M | — |
| Delin Ren | Executive Director | 4M | — |
| Ying Wu | Executive Vice President & Executive Director | 1M | male |
| Jianguo Ma | Senior Vice President & President of Shanghai Langhua Pharmaceutical | — | — |
| Jianhua Cai | Senior Vice President of Via Biotech Shanghai | — | male |
| Rongqiang Liu | Senior Vice President of Via Biotech Shanghai | — | — |
| Susan Chen | Chief Technology Officer | — | — |
| Wei Xiong | Chief Financial Officer | — | male |
| Xianyong Bu | CBO & EVice President of Viva Biotech (Shanghai) | — | male |
| Xueheng Cheng | Chief Technology Officer | — | male |
| Zhixiong Ye | Chief Scientific Officer | — | — |
| Derek Ren | Chief Executive Officer of Viva Biotech (Shanghai) Ltd. | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 1873.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
